Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Multiple clinical trials have demonstrated that oxerutin reduces edema and pain associated with venous disease
human bioavailability is unknown Subcutaneous injection Human subcutaneous bioavailability and pharmacokinetics are unknown Factor Convenience Oral capsules No mixing or syringe math Subcutaneous injection Requires reconstitution, sterile supplies, and injection-site planning Factor Evidence limits Oral capsules No controlled human dose, benefit, or safety trial Subcutaneous injection No controlled human dose, benefit, or safety trial Factor Can the amounts be treated as equal
Long-term safety has not yet been established
Limited clinical data outside dermatology research
%20b12.png)
